CN112646886A - Application of FOXD1 in invasive breast cancer - Google Patents

Application of FOXD1 in invasive breast cancer Download PDF

Info

Publication number
CN112646886A
CN112646886A CN202011557892.7A CN202011557892A CN112646886A CN 112646886 A CN112646886 A CN 112646886A CN 202011557892 A CN202011557892 A CN 202011557892A CN 112646886 A CN112646886 A CN 112646886A
Authority
CN
China
Prior art keywords
breast cancer
foxd1
subtype
invasive breast
basl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011557892.7A
Other languages
Chinese (zh)
Other versions
CN112646886B (en
Inventor
任栋
杨春潇
张鑫
王斌
姜春林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangmen Central Hospital
Original Assignee
Jiangmen Central Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangmen Central Hospital filed Critical Jiangmen Central Hospital
Priority to CN202011557892.7A priority Critical patent/CN112646886B/en
Publication of CN112646886A publication Critical patent/CN112646886A/en
Application granted granted Critical
Publication of CN112646886B publication Critical patent/CN112646886B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention makes clear for the first time that FOXD1 is significantly up-regulated in multiple molecular subtypes of invasive breast cancer, especially in the BasL subtype. Furthermore, overexpression of FOXD1 specifically predicted bone metastasis in patients with multiple molecular subtypes of invasive breast cancer. Importantly, silencing FOXD1 inhibited invasive breast cancer bone metastasis in vivo, but had no effect on liver, brain and lung metastasis. Therefore, the invention provides an application scheme of FOXD1 in invasive breast cancer, and provides a new path for improving the survival quality of breast cancer patients.

Description

Application of FOXD1 in invasive breast cancer
Technical Field
The invention belongs to the field of biomedicine, and particularly relates to application of FOXD1 in invasive breast cancer.
Background
Breast cancer (BCa) is the most common malignancy in women. Although the treatment of primary breast cancer has made major progress in recent decades with the progress of precision medicine, cancer metastasis remains the cause of most cancer deaths. The most common metastatic organs of breast cancer include bone, brain, liver, lung, and 15 years follow-up studies found that as many as 51.5% of breast cancer patients develop metastasis. Bone is the main site of metastasis of breast cancer, and the subtypes that develop bone metastasis are mainly LumA, LumB and HER 2. Once bone metastasis of breast cancer occurs, a range of bone-related complications can develop, including fractures, intractable pain, hypercalcemia, or nerve compression syndrome, which severely affect the quality of life and the survival time of breast cancer patients.
FOXD1(Forkhead Box D1, HGNC:3802) belongs to the Forkhead Box (Fox) transcription factor family, characterized by a unique Forkhead domain, and FOXD1 has been reported to play an important role in retinal and renal development, as well as to modulate inflammatory responses and prevent autoimmunity.
The present invention has been made in view of the above background, in conjunction with the research results that the present invention has been made for the first time.
Disclosure of Invention
The invention provides at least one of the following technical schemes:
the invention relates to application of a reagent for detecting the expression level of FOXD1 in preparing a product for diagnosing whether a subject has invasive breast cancer.
The invention also relates to application of the reagent for detecting the FOXD1 expression level in preparing a product for predicting the survival prognosis of an invasive breast cancer subject.
The invention also relates to application of the reagent for detecting the expression level of FOXD1 in preparing a product for predicting bone metastasis tendency of an invasive breast cancer subject.
The invention also relates to application of the FOXD1 inhibitory reagent in preparation of a medicine for preventing, inhibiting and/or treating invasive breast cancer bone metastasis.
The beneficial effects obtained by the invention comprise at least any one of the following:
the invention makes clear for the first time that FOXD1 is significantly up-regulated in multiple molecular subtypes of invasive breast cancer, especially in the BasL subtype. Furthermore, overexpression of FOXD1 specifically predicted bone metastasis in patients with multiple molecular subtypes of invasive breast cancer. Importantly, silencing FOXD1 inhibited invasive breast cancer bone metastasis in vivo, but had no effect on liver, brain and lung metastasis. Therefore, the invention provides an application scheme of FOXD1 in invasive breast cancer, and provides a new path for improving the survival quality of breast cancer patients.
Drawings
FIG. 1: IHC detects the expression of FOXD1 in different tissues; in the figure, benign represents benign hyperplasia of mammary glands tissue, precan represents malignant atypical hyperplasia of mammary glands tissue, In situ represents In situ breast cancer tissue, and invadeve represents Invasive breast cancer tissue; BasL represents a BasL type invasive breast cancer tissue, Her2 represents a Her2 type invasive breast cancer tissue, LumA represents a LumA type invasive breast cancer tissue, and LumB represents a LumB type invasive breast cancer tissue;
FIG. 2: analysis of FOXD1 expression and different survival periods among BasL subtypes and other subtypes; in the figure, OS represents the total survival period, DMFS represents the survival period without distant metastasis, BoMFS represents the survival period without bone metastasis, LiMFS represents the survival period without liver metastasis, BrMFS represents the survival period without brain metastasis, LuMFS represents the survival period without lung metastasis, Other represents non-BasL subtype invasive breast cancer tissues, including Her2, LumA and LumB subtype invasive breast cancer tissues; cutoff (SI) indicates a cutoff value set according to SI, L indicates low expression of FOXD1, and H indicates high expression of FOXD 1;
FIG. 3: constructing a down-regulated expression FOXD1 model in a breast cancer cell line, taking Scr as a reference, and respectively constructing a down-regulated expression model by using two FOXD1 shRNAs for sh #1 and sh # 2;
FIG. 4: down-regulation of FOXD1 effect on bone metastasis in vivo, panel a is a schematic imaging; panel B is a bone X-ray, panel C is a bone H & E staining, panel D is an osteolytic score assessed by X-ray, panel E is tumor area assessed according to H & E, panel F is a survival curve without bone metastasis, panel G is tumor area metastatic to the brain, panel H is tumor area metastatic to the liver, panel I is tumor area metastatic to the lung, and Scramble is a control.
Detailed Description
Reference will now be made in detail to embodiments of the invention, one or more embodiments of which are described below. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment.
The invention provides an implementation mode of application of a reagent for detecting the expression level of FOXD1 in preparation of a product for diagnosing whether a subject has invasive breast cancer. "detection" in the context of the present invention is to be understood in its broadest sense, including both qualitative and quantitative. In some embodiments, FOXD1 expression level in invasive breast cancer is significantly higher than benign hyperplasia of mammary glands, malignant atypical hyperplasia of mammary glands or in situ breast cancer, and thus, whether a subject suffers from invasive breast cancer can be effectively judged by detecting FOXD1 expression level. For example, if a subject's FOXD1 expression level is higher than a set cutoff value, then it is diagnosed as having invasive breast cancer.
In some embodiments, the invasive breast cancer is selected from the BasL subtype, Her2 subtype, LumA subtype, or LumB subtype; in preferred embodiments, the invasive breast cancer is the BasL subtype; the expression level of FOXD1 in the BasL subtype invasive breast cancer is obviously higher than that of a Her2 subtype, a LumA subtype or a LumB subtype, so that whether a subject suffers from the BasL subtype invasive breast cancer or not can be specifically judged by detecting the expression level of FOXD 1. For example, if the subject FOXD1 expression level is higher than the set cutoff value, it is diagnosed as having BasL subtype aggressive breast cancer.
The invention also provides an implementation mode of the application of the reagent for detecting the FOXD1 expression level in preparing a product for predicting the survival prognosis of an invasive breast cancer subject. By "predicting" herein is meant predicting the predisposition or risk of a subject to develop a disease/metastasis before the subject does not develop the disease/metastasis. In some embodiments, where the invasive breast cancer subject is the BasL subtype, the product is used to predict overall survival and/or distant metastasis free survival of the subject. For example, overall survival, or distant metastasis-free survival of a subject can be predicted by detecting FOXD1 expression levels in a BasL subtype aggressive breast cancer subject; wherein the shorter overall survival, the greater the risk of death; or the shorter the survival without distant metastasis, the greater the risk of distant metastasis. Predicting a subject to have poor overall survival (or output corresponding survival time, or higher risk of death), poor distant metastasis-free survival (or input corresponding distant metastasis-free time, or higher risk of distant metastasis) if the BasL subtype aggressive breast cancer subject FOXD1 expression level is higher than the set cutoff value; the choice of intervention means may be guided.
In some embodiments, where the invasive breast cancer subject is a non-BasL subtype, the product may predict distant metastasis-free survival of the subject; for example, distant metastasis-free survival of a subject can be predicted by detecting FOXD1 expression levels in a non-BasL subtype aggressive breast cancer subject. Predicting that the subject has poor survival without distant metastasis (or input a corresponding time to no distant metastasis, or higher risk of distant metastasis) if the non-BasL subtype aggressive breast cancer subject FOXD1 expression level is higher than the set cutoff value; the choice of intervention means may be guided. In some embodiments, the non-BasL subtype is selected from the Her2 subtype, the LumA subtype, or the LumB subtype.
The invention also provides an implementation mode of the application of the reagent for detecting the expression level of FOXD1 in preparing a product for predicting the tendency of bone metastasis of an invasive breast cancer subject. In some embodiments, the invasive breast cancer subject is selected from the BasL subtype, Her2 subtype, LumA subtype, or LumB subtype. Bone metastasis can be specifically predicted in different typed aggressive breast cancer subjects. For example, the predisposition/risk of a subject to develop bone metastasis can be predicted by detecting FOXD1 expression levels in an aggressive breast cancer subject. For example, when the FOXD1 expression level of an invasive breast cancer subject is higher than a set cutoff value, the subject can be predicted to have a high tendency/risk of bone metastasis.
"expression" refers to transcription into oligonucleotides, translation into polypeptides or their modifications, splicing, etc., and the level can be expressed in high/low form or in a specific quantitative value. In some embodiments, the expression level comprises mRNA levels and protein levels. In some embodiments, the reagents comprise primers, probes, antibodies, or aptamers that detect the expression level of FOXD 1. Wherein, it is understood that primers or probes are used to detect the mRNA level of FOXD1, and antibodies or aptamers are used to detect the protein level of FOXD1, which can be obtained by conventional design/screening in the art or commercially available, and which can also be supported on a solid support. In some embodiments, detecting FOXD1mRNA levels can employ a variety of detection modalities, such as fluorescent quantitative PCR, rolling circle nucleic acid amplification, loop-mediated isothermal amplification, strand displacement amplification, and the like. In some embodiments, the protein level of FOXD1 can be detected by ELISA, chemiluminescence, immunohistochemistry, and the like.
The cutoff value is also referred to herein as a cutoff value, and those skilled in the art can set an effective cutoff value for diagnosing/predicting the aforementioned various diseases or process risks according to the specificity, sensitivity, etc. of the prepared diagnostic or predictive product, for example, by counting the FOXD1 levels of a large population of target subjects and setting them according to the product target, or even setting the corresponding cutoff values using a computer model, or by combining them with other markers.
The invention also relates to an implementation mode, namely application of the FOXD1 inhibitory reagent in preparation of a medicine for preventing, inhibiting and/or treating invasive breast cancer bone metastasis. In some embodiments, the inhibitory agent of FOXD1 is selected from the group consisting of: substances capable of completely or partially inhibiting the expression of the FOXD1 gene, substances capable of completely or partially inhibiting the FOXD1 protein from exerting efficacy; in some embodiments, the inhibitory agent of FOXD1 is selected from the group consisting of: proteins, oligonucleotides, oligonucleotide expression vectors, small molecule compounds. In some embodiments, the inhibitory agent of FOXD1 is, for example, an interfering RNA, an antisense oligonucleotide, or CRISPRi.
The product of the invention is obtained by detecting a sample from a subject, wherein the sample can be an isolated body fluid sample or a tumor sample; body fluids include, but are not limited to, blood, plasma, serum, lymph, cerebrospinal fluid, synovial fluid, urine, saliva, mucus, and the like; the form of the tumor sample includes, but is not limited to, the form of a living tissue, a paraffin-embedded tissue, a frozen tissue, and the like. The subject's sample may also be selected from cells that can be isolated from the subject, such as peripheral blood mononuclear cells, T lymphocytes, B lymphocytes, circulating tumor cells, and the like.
"bone metastasis free" in the medical field means that bone metastasis does not occur, and generally, a collected tumor sample is analyzed and classified as a bone metastasis free tumor sample if the tumor sample does not have bone metastasis, and it should be understood by those skilled in the art that the bone metastasis free tumor sample may be a tumor sample in which no metastasis occurs, and may also be a tumor sample in which other non-bone metastasis (such as liver, brain, lung) occurs. The same understanding is understood as "no lung metastasis", "no liver metastasis" and "no brain metastasis".
The invention is further illustrated by the following specific examples, which, however, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The experimental procedures, in which specific conditions are not specified in the examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers.
Example 1 FOXD1 was highly expressed in invasive breast cancer tissue
Clinical samples were collected from the central hospital in the Jiangmen city, 67 cases of benign hyperplastic breast lesions, 30 cases of malignant atypical hyperplastic breast lesions, 49 cases of in situ breast cancer tissues and 394 cases of invasive breast cancer tissues, wherein 394 cases of invasive breast cancer tissues were typed, 104 cases of BasL type, 96 cases of Her2 type, 95 cases of LumA type and 99 cases of LumB type.
Immunohistochemistry (IHC) staining of the above tissues: firstly, thermally treating a tissue slice at 65 ℃ for 1h, and then dewaxing the tissue slice in xylene for 2 times and 5min each time; hydrating the slices with 100% ethanol, 95% ethanol, 85% ethanol, 75% ethanol and pure water for 1min each time; taking out, adding 3% hydrogen peroxide dropwise, incubating at room temperature for 10min, and inactivating endogenous peroxidase; placing the slices in a container containing EDTA pH9.0 repairing solution, and repairing under high pressure for 10 min; taking out the slices, surrounding the tissues by an immunohistochemical pen, rinsing the tissues for 3min by using PBS buffer solution, dripping goat serum confining liquid (reagent A) after spin-drying, and incubating for 20min at room temperature; removing the reagent A, dropwise adding FOXD1 primary antibody working solution diluted by the antibody diluent, and incubating overnight at 4 ℃; removing primary antibody, rinsing with PBST buffer solution for 3 times and 5min each time, spin-drying, dripping biotin-labeled secondary antibody working solution (reagent B), and incubating at room temperature for 20 min; discarding the reagent B, rinsing with PBST buffer solution for 3 times and 5min each time, dripping horse radish peroxidase-labeled streptavidin working solution (reagent C) after spin-drying, and incubating at room temperature for 10 min; removing the reagent C, rinsing the mixture for 3 times with PBST buffer solution for 5min each time, dripping DAB developing solution after spin-drying, and incubating the mixture for 1-5 min at room temperature; immersing the slices in tap water to stop color development, re-staining with hematoxylin staining solution for 1min, washing with tap water, and differentiating with hydrochloric acid alcohol for 5 s; dehydrating the slices with 75% ethanol, 85% ethanol, 95% ethanol, and 100% ethanol for 3min each time, and drying in a drying oven at 37 deg.C for 30min to obtain environmentally friendly resin sealed tablet. And comprehensively scoring the expression of the protein according to the positive rate and the staining depth of the immunohistochemical tumor cells. First, scoring is performed according to the positive rate of the tumor cells of the section, and the tumor cells without positive: 0 minute; < 10% of tumor cells positive: 1 minute; 10% -35% of the tumor cells are positive: 2 min; 35-70% of the tumor cells are positive: 3 min; > 70% of tumor cells are positive: and 4, dividing. Scoring is then performed according to the overall depth of staining of positive tumor cells: no staining signal was 0 min; the light yellow is 1 minute; the deep yellow is 2 points; the brown-yellow color is 3 points. Finally, the positive rate score is multiplied by the Staining intensity score to obtain immunohistochemical Staining Scores (SI) of 9 grades of 0, 1, 2, 3, 4, 6, 8, 9 or 12.
As shown In FIG. 1, FOXD1 was detected mainly In the nucleus (FIG. 1A), and FOXD1 expression was significantly increased In Invasive breast cancer tissue (Invasive) compared to benign hyperplastic breast lesion tissue (benign) and malignant atypical hyperplastic breast lesion tissue (Precan.) and In situ breast cancer tissue (In situ) (FIG. 1B). Therefore, whether a subject suffers from invasive breast cancer can be effectively judged by detecting the expression level of FOXD 1.
The treatment strategies for different molecular subtypes of breast cancer are very different, and the research result unexpectedly finds that FOXD1 has difference in different molecular subtypes of breast cancer. FOCD1 was differentially upregulated in all breast cancer subtypes compared to benign proliferative breast lesions, and was particularly significantly elevated in the BasL subtype (FIGS. 1C and 1D). Therefore, whether the subject suffers from BasL subtype aggressive breast cancer can be specifically judged by detecting the expression level of the FOXD 1.
Example 2 overexpression of FOXD1 specifically predicts bone metastasis from various molecular subtypes of breast cancer
In the embodiment, Kaplan-Meier survival analysis is adopted, different cutoff values are set for analysis according to different sample objects, the cutoff values are set according to the middle level of the SI sample to be analyzed, the middle level is FOXD1 high expression, and the middle level is FOXD1 low expression.
As shown in fig. 2, FOXD1 levels in invasive breast cancer tissues of the BasL subtype correlated with Overall Survival (OS) and Distant Metastasis Free Survival (DMFS), while FOXD1 levels in invasive breast cancer tissues of other subtypes (including lumineal a, lumineal B, and HER2) correlated only with Distant Metastasis Free Survival (DMFS) (fig. 2A-D). Therefore, the overall survival or distant metastasis-free survival of the subject can be predicted by detecting the expression level of FOXD1 in a BasL subtype invasive breast cancer subject, and the distant metastasis-free survival of the subject can also be predicted by detecting the expression level of FOXD1 in a non-BasL subtype invasive breast cancer subject.
Breast cancer has a high propensity for metastasis to bone, lung, liver and brain and is often highly metastatic to bone depending on molecular markers, such as the LumA, LumB and Her2 subtypes; BasL is transferred to solid organs such as lung and brain. Surprisingly, it was found from the results of the study that overexpression of FOXD1, whether of the BasL subtype or of other subtypes (including luminel a, luminel B and HER2), was only associated with bone metastasis free survival (BoMFS) and not with brain metastasis free survival (BrMFS), liver metastasis free survival (LiMFS) and lung metastasis free survival (LuMFS). It is noteworthy that even in the BasL subtype with high potential for solid organ metastasis, overexpression of FOXD1 could only specifically predict BoMFS (FIGS. 2E-L). Therefore, the tendency/risk of the subject to develop bone metastasis can be predicted by detecting the expression level of FOXD1 in the invasive breast cancer subject.
Example 3 Down-Regulation of FOXD1 specifically inhibits breast cancer bone metastasis in vivo
Selecting BasL type breast cancer cells MDA-MB-231 and MDA-MB-468 to construct a cell model for down-regulating FOXD1, wherein cell lines are purchased from a cell bank of Chinese academy of sciences, cells grow in 1640 culture medium (Hyclone), and 10% fetal calf serum, 500mg/ml glutamine, 250mg/ml chloramphenicol and 200mg/ml penicillin are added at the same time, and the cells are cultured in a cell culture box with the temperature of 37 ℃ and the carbon dioxide concentration of 5%; according to the state and density of the cells to be observed, the culture medium is changed every 2 to 3 days, and the cells are preferably used in an experiment when the cell density is as high as 70 to 80%.
Establishment of a FOXD1 cell model under reduced conditions: human FOXD1shRNA plasmid (RNA interference plasmid for short) for stably expressing luciferase is constructed by adopting a retrovirus vector (pSuper-retro-puro), FOXD1sh #1 and FOXD1sh #2 are respectively constructed, and the construction is finished by Ruibo biotechnology limited company in Guangzhou city. The FOXD1shRNA plasmid and a control plasmid (Scr.) thereof are respectively infected with MAD-MB-231 and MDA-MB-468, and the expression condition of FOXD1 is detected by adopting fluorescent quantitative PCR and Western blotting.
Fluorescent quantitative PCR: taking about 100mg of tissue/cell to be detected, grinding in liquid nitrogen with a mortar, adding TRizol, splitting at room temperature for 10min, adding 0.2ml of chloroform into 1ml of TRizol splitting liquid, violently shaking for 30s, and standing for 5 min; centrifuging at 4 deg.C for 15min at 12,000g, sucking supernatant into a new centrifuge tube, adding equal volume of isopropanol, beating uniformly, standing for 10min, centrifuging at 4 deg.C for 5min at 12,000g, washing RNA precipitate with DEPC water solution containing 75% ethanol for 3 times, drying slightly, and dissolving RNA with DEPC water. After the concentration is measured, reverse transcription is carried out according to the instruction of PrimeScript RT reagent Kit: detecting and analyzing by using a 2ddCt relative quantitative method on a 7500 real-time quantitative PCR system according to the specification of SYBR Premix Ex Taq II Kit, wherein an internal reference gene is GAPDH, and calculating the relative mRNA expression quantity of a target gene; primers for detecting FOXD1mRNA and its reference gene were designed and synthesized by Ruibo Biotech, Inc., Guangzhou.
Western blotting: taking about 100mg of cells/tissues to be detected, grinding the cells/tissues in a liquid nitrogen by using a mortar, adding RIPA lysate to perform ice lysis for 30min, collecting the lysate, centrifuging the lysate for 15min at 4 ℃ under the condition of 12,000g, collecting supernatant, performing protein quantification according to the BCA protein quantification kit instruction, adding 5 times of loading buffer solution with the volume of 1/4 into the supernatant, performing boiling water bath for 10min, and performing ice bath for 5 min. Using SDS PAGE protein electrophoresis system, the loading amount is 30 μ g total protein, the electrophoresis parameters are 10% separation gel, 5% concentration gel, 100V electrophoresis 90min until the trypan blue indicator migrates to the bottom, then electrotransfer is performed, and the PVDF membrane with 0.45 μm is used, and 300mAl ice bath is used for 90 min. After the electrotransformation is finished, sealing the membrane by using 5% skimmed milk powder, rinsing by TBST for 3 times and 5min, adding FOXD1 antibody, incubating overnight at 4 ℃, rinsing by TBST for 3 times and 5min, adding secondary antibody diluted by sealing liquid, incubating at room temperature for 1h, rinsing by TBST for 3 times and 5min, adding ECL luminous liquid, placing in a pressing clamp, exposing to X-ray negative for 1-20min, and developing and fixing with alpha-tubulin as a control.
As shown in FIG. 3, the FOXD1 model was successfully constructed in MDA-MB-231 and MDA-MB-468 cell lines.
MDA-MB-231 down-regulated FOXD1 cell model constructed by FOXD1sh #1 is used for constructing a mouse in-vivo model, 4-5 weeks old nude mice are taken as research objects, and the density is 1 multiplied by 106one/mL of cells were injected into the left ventricle of mice. After 6 weeks of inoculation, mice were examined for metastasis (bone, brain, lung and liver) by in vivo imaging system and Xray, and embedded sections were HE stained and observed. Wherein the degree of bone destruction was scored according to Xray for each animal and bone metastasis was scored according to the following criteria: 0: no transfer; 1: the bone lesion covers a bone width of less than 1/4; 2: covering the width of the bone 1/4-1/2 with the bone injury; 3: covering the width of the bone 1/2-3/4 with the bone injury; 4: the bone lesion covers a bone width greater than 3/4; the bone metastasis score for each animal was derived from the limb composite score. HE evaluation of tumor area comprehensive limb scores were made based on the area of bone destruction in each animal, expressed as square millimeters.
As shown in FIG. 4, silencing FOXD1 inhibited bone metastasis of breast cancer, significantly reduced the area of bone metastasis foci formation and the extent of bone destruction, and prolonged the life span of mice without bone metastasis (FIGS. 4A-F), while silencing FOXD1 had no effect on breast cancer liver metastasis, lung metastasis, and brain metastasis (FIGS. 4G-I). Therefore, the inhibitory agent of FOXD1 can be used for preventing, inhibiting and/or treating invasive breast cancer bone metastasis.

Claims (10)

1. Application of a reagent for detecting the expression level of FOXD1 in preparing a product for diagnosing whether a subject has invasive breast cancer.
2. Use according to claim 1, characterized in that: the invasive breast cancer is selected from BasL subtype, Her2 subtype, LumA subtype or LumB subtype; preferably, the aggressive breast cancer is the BasL subtype.
3. Application of reagent for detecting FOXD1 expression level in preparation of products for predicting survival prognosis of invasive breast cancer subjects.
4. Use according to claim 3, characterized in that: when the invasive breast cancer subject is of the BasL subtype, the product is used for predicting overall survival and/or distant metastasis-free survival of the subject.
5. Use according to claim 3, characterized in that: when the invasive breast cancer subject is not a BasL subtype, the product can predict the distant metastasis-free survival time of the subject; optionally, the non-BasL subtype is selected from the Her2 subtype, the LumA subtype, or the LumB subtype.
6. Application of reagent for detecting expression level of FOXD1 in preparation of product for predicting bone metastasis tendency of invasive breast cancer subjects.
7. Use according to claim 6, characterized in that: the aggressive breast cancer subject is selected from the BasL subtype, the Her2 subtype, the LumA subtype, or the LumB subtype.
8. Use according to any one of claims 1 to 7, characterized in that: the expression levels include mRNA levels and protein levels; optionally, the reagents include primers, probes, antibodies or aptamers that detect the expression level of FOXD 1.
The application of the FOXD1 inhibitory reagent in preparing a medicine for preventing, inhibiting and/or treating invasive breast cancer bone metastasis.
10. Use according to claim 9, characterized in that: the inhibitory agent of FOXD1 is selected from the group consisting of: substances capable of completely or partially inhibiting the expression of the FOXD1 gene, substances capable of completely or partially inhibiting the FOXD1 protein from exerting efficacy; optionally, the inhibitory agent of FOXD1 is selected from the group consisting of: proteins, oligonucleotides, oligonucleotide expression vectors, small molecule compounds.
CN202011557892.7A 2020-12-23 2020-12-23 Application of FOXD1 in invasive breast cancer Active CN112646886B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011557892.7A CN112646886B (en) 2020-12-23 2020-12-23 Application of FOXD1 in invasive breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011557892.7A CN112646886B (en) 2020-12-23 2020-12-23 Application of FOXD1 in invasive breast cancer

Publications (2)

Publication Number Publication Date
CN112646886A true CN112646886A (en) 2021-04-13
CN112646886B CN112646886B (en) 2022-10-18

Family

ID=75362834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011557892.7A Active CN112646886B (en) 2020-12-23 2020-12-23 Application of FOXD1 in invasive breast cancer

Country Status (1)

Country Link
CN (1) CN112646886B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
CN108949984A (en) * 2018-07-25 2018-12-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Application of the gene DESI2 in three negative breast cancer diagnosis, prognosis evaluation and treatment
CN110218796A (en) * 2019-06-27 2019-09-10 江门市中心医院 New target drone PCDHB2 for Bone of Breast Cancer transfer diagnosis and treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
CN108949984A (en) * 2018-07-25 2018-12-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Application of the gene DESI2 in three negative breast cancer diagnosis, prognosis evaluation and treatment
CN110218796A (en) * 2019-06-27 2019-09-10 江门市中心医院 New target drone PCDHB2 for Bone of Breast Cancer transfer diagnosis and treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JINHUAWANG等: "Members of FOX family could be drug targets of cancers", 《PHARMACOLOGY AND THERAPEUTICS》 *
MIGUEL NAVA等: "Utilization of NGs technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance", 《SCIENTIFIC REPORTS》 *
余元勋: "《中国分子乳腺癌学》", 31 August 2017 *
李贵喜: "FOXF2调控乳腺癌骨转移的机制", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 *

Also Published As

Publication number Publication date
CN112646886B (en) 2022-10-18

Similar Documents

Publication Publication Date Title
Jamaspishvili et al. Clinical implications of PTEN loss in prostate cancer
Vishal et al. Role of Runx2 in breast cancer-mediated bone metastasis
Kunovsky et al. The use of biomarkers in early diagnostics of pancreatic cancer
Lohaus et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Wislez et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
Osada et al. Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel–Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma
Horiuchi et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma
Fisher et al. Accurate detection of BRAF p. V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays
Guan et al. MDA-9 and GRP78 as potential diagnostic biomarkers for early detection of melanoma metastasis
Zhang et al. S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer
Xia et al. ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma
US9857375B2 (en) Cancer marker and utilization thereof
Ren et al. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas
Lin et al. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1
CN112501299A (en) Method for predicting recurrence and metastasis of liver cancer and application
An et al. Circulating microvesicles from pancreatic cancer accelerate the migration and proliferation of PANC-1 cells
TW201248147A (en) Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients
CN110218796B (en) New target PCDHB2 for breast cancer bone metastasis diagnosis and treatment
Fang et al. Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K
CN112646886B (en) Application of FOXD1 in invasive breast cancer
WO2013191242A1 (en) Test method and treatment means for small cell lung cancer having poor prognosis
Scott et al. The pancreas as a site of metastasis or second primary in patients with small bowel neuroendocrine tumors
JP2011520456A (en) Combined method for predicting response to anti-cancer therapy
Li et al. CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry
Zhang et al. Expression and significance of molecular biomarkers in esophageal carcinoma in different nationalities patients in Xinjiang

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210413

Assignee: Jiangmen Yifengtang Biotechnology Co.,Ltd.

Assignor: JIANGMEN CENTRAL Hospital

Contract record no.: X2023980036579

Denomination of invention: Application of FOXD1 in invasive breast cancer

Granted publication date: 20221018

License type: Common License

Record date: 20230614

EE01 Entry into force of recordation of patent licensing contract